NASDAQ:NGM - NGM Biopharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.25
  • Forecasted Upside: 73.05 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$20.37
▲ +0.49 (2.46%)
1 month | 3 months | 12 months
Get New NGM Biopharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NGM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NGM

Average Price Target: $35.25
▲ +73.05% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for NGM Biopharmaceuticals in the last 3 months. The average price target is $35.25, with a high forecast of $44.00 and a low forecast of $22.00. The average price target represents a 73.05% upside from the last price of $20.37.

Buy

The current consensus among 6 polled investment analysts is to buy stock in NGM Biopharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2021Stifel NicolausLower Price TargetBuy$43.00 ➝ $22.00Medium
5/24/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$52.00 ➝ $22.00N/A
3/5/2021Raymond JamesBoost Price TargetStrong-Buy$50.00 ➝ $52.00High
3/5/2021Chardan CapitalBoost Price TargetBuy$39.00 ➝ $44.00High
2/9/2021The Goldman Sachs GroupBoost Price TargetBuy$28.00 ➝ $38.00Low
1/8/2021Raymond JamesBoost Price TargetStrong-Buy$32.00 ➝ $50.00Low
1/5/2021Stifel NicolausReiterated RatingTop PickN/A
12/21/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$28.00 ➝ $44.00Medium
12/21/2020Smith Barney CitigroupBoost Price Target$28.00 ➝ $44.00Medium
12/14/2020B. RileyBoost Price TargetBuy$30.00 ➝ $38.00Medium
10/20/2020Chardan CapitalReiterated RatingBuy$39.00High
8/14/2020B. RileyReiterated RatingBuy$30.00High
8/13/2020Chardan CapitalLower Price TargetBuy$40.00 ➝ $39.00High
7/30/2020Piper SandlerInitiated CoverageOverweight$30.00High
7/7/2020Chardan CapitalInitiated CoverageBuy$40.00High
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$30.00High
5/21/2020B. RileyReiterated RatingBuy$30.00Low
5/18/2020Stifel NicolausReiterated RatingBuy$32.00Medium
5/14/2020Raymond JamesBoost Price TargetStrong-Buy$31.00 ➝ $32.00Medium
4/19/2020Raymond JamesInitiated CoverageStrong-Buy$31.00Low
4/6/2020Raymond JamesInitiated CoverageStrong-Buy$31.00High
3/27/2020CitigroupLower Price TargetBuy$34.00 ➝ $28.00High
3/23/2020CowenReiterated RatingBuy$30.00Low
3/19/2020Stifel NicolausLower Price TargetBuy$33.00 ➝ $32.00High
3/19/2020B. RileyReiterated RatingBuy$30.00High
2/26/2020B. RileyBoost Price Target$24.00 ➝ $30.00Low
2/25/2020Stifel NicolausBoost Price TargetBuy$26.00 ➝ $33.00High
2/25/2020CitigroupBoost Price TargetPositive ➝ Buy$31.00 ➝ $34.00High
2/24/2020B. RileyReiterated RatingBuy$24.00 ➝ $24.00High
2/24/2020CowenReiterated RatingBuyHigh
2/11/2020B. RileyReiterated RatingBuy$24.00Medium
12/10/2019CitigroupReiterated RatingBuy$31.00Medium
12/4/2019Stifel NicolausReiterated RatingBuy$26.00High
10/17/2019B. RileyInitiated CoverageBuy$24.00High
8/14/2019Stifel NicolausReiterated RatingBuy$26.00Low
6/24/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$26.00High
5/20/2019CowenReiterated RatingBuy$25.00Medium
4/29/2019CitigroupInitiated CoverageBuy ➝ Buy$29.00High
4/29/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$22.00Medium
4/29/2019CowenInitiated CoverageOutperform ➝ Outperform$25.00Medium
(Data available from 6/21/2016 forward)
NGM Biopharmaceuticals logo
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase Ib clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase II clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438, which are in preclinical investigational studies for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $20.37
Low: $19.43
High: $20.40

50 Day Range

MA: $23.21
Low: $15.06
High: $28.89

52 Week Range

Now: $20.37
Low: $14.90
High: $32.12

Volume

1,449,100 shs

Average Volume

358,340 shs

Market Capitalization

$1.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2

Frequently Asked Questions

What sell-side analysts currently cover shares of NGM Biopharmaceuticals?

The following Wall Street research analysts have issued stock ratings on NGM Biopharmaceuticals in the last twelve months: B. Riley, Chardan Capital, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Piper Sandler, Raymond James, Smith Barney Citigroup, Stifel Nicolaus, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for NGM.

What is the current price target for NGM Biopharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for NGM Biopharmaceuticals in the last year. Their average twelve-month price target is $35.25, suggesting a possible upside of 73.0%. Chardan Capital has the highest price target set, predicting NGM will reach $44.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $22.00 for NGM Biopharmaceuticals in the next year.
View the latest price targets for NGM.

What is the current consensus analyst rating for NGM Biopharmaceuticals?

NGM Biopharmaceuticals currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NGM will outperform the market and that investors should add to their positions of NGM Biopharmaceuticals.
View the latest ratings for NGM.

What other companies compete with NGM Biopharmaceuticals?

How do I contact NGM Biopharmaceuticals' investor relations team?

NGM Biopharmaceuticals' physical mailing address is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650 243 5555 and its investor relations email address is [email protected] The official website for NGM Biopharmaceuticals is www.ngmbio.com.